BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crimi C, Ferri S, Crimi N. Bronchiectasis and asthma: a dangerous liaison? Curr Opin Allergy Clin Immunol 2019;19:46-52. [PMID: 30516546 DOI: 10.1097/ACI.0000000000000492] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 La Via L, Sanfilippo F, Cuttone G, Dezio V, Falcone M, Brancati S, Crimi C, Astuto M. Use of ketamine in patients with refractory severe asthma exacerbations: systematic review of prospective studies. Eur J Clin Pharmacol 2022. [PMID: 36008492 DOI: 10.1007/s00228-022-03374-3] [Reference Citation Analysis]
2 Wang M, Tang K, Gao P, Lu Y, Wang S, Wu X, Zhao J, Xie J. Club cell 10-kDa protein (CC10) as a surrogate for identifying type 2 asthma phenotypes. J Asthma 2022;:1-9. [PMID: 35168451 DOI: 10.1080/02770903.2022.2040531] [Reference Citation Analysis]
3 Crimi C, Campisi R, Nolasco S, Ferri S, Cacopardo G, Impellizzeri P, Pistorio MP, Fagone E, Pelaia C, Heffler E, Crimi N. Type 2-High Severe Asthma with and without Bronchiectasis: A Prospective Observational Multicentre Study. J Asthma Allergy 2021;14:1441-52. [PMID: 34880630 DOI: 10.2147/JAA.S332245] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
4 Ma D, Cruz MJ, Ojanguren I, Romero-Mesones C, Varona-Porres D, Munoz X. Risk factors for the development of bronchiectasis in patients with asthma. Sci Rep 2021;11:22820. [PMID: 34819607 DOI: 10.1038/s41598-021-02332-w] [Reference Citation Analysis]
5 Kim T, Lee H, Sim YS, Yang B, Park HY, Ra SW, Jang HJ, Yoo SJ, Kim SH, Sohn JW, Yoon HJ, Oh YM, Kwon YS, Choi H. Respiratory symptoms and health-related quality of life in post-tuberculosis subjects with physician-diagnosed bronchiectasis: a cross-sectional study. J Thorac Dis 2021;13:4894-902. [PMID: 34527328 DOI: 10.21037/jtd-20-3028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Menzella F, Bonavia M, Bonini M, D'Amato M, Lombardo S, Murgia N, Patella V, Triggiani M, Pelaia G. Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series. J Asthma Allergy 2021;14:149-61. [PMID: 33654412 DOI: 10.2147/JAA.S295676] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Douros K, Sardeli O, Prountzos S, Galani A, Moriki D, Alexopoulou E, Priftis KN. Asthma-Like Features and Anti-Asthmatic Drug Prescription in Children with Non-CF Bronchiectasis. J Clin Med 2020;9:E4009. [PMID: 33322440 DOI: 10.3390/jcm9124009] [Reference Citation Analysis]
8 Choi H, Lee H, Ryu J, Chung SJ, Park DW, Sohn JW, Yoon HJ, Kim SH. Bronchiectasis and increased mortality in patients with corticosteroid-dependent severe asthma: a nationwide population study. Ther Adv Respir Dis 2020;14:1753466620963030. [PMID: 33059535 DOI: 10.1177/1753466620963030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
9 Crimi C, Campisi R, Cacopardo G, Intravaia R, Nolasco S, Porto M, Pelaia C, Crimi N. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities. World Allergy Organ J 2020;13:100462. [PMID: 32994855 DOI: 10.1016/j.waojou.2020.100462] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
10 de la Rosa Carrillo D, Prados Sánchez C. Epidemiología y diversidad geográfica de las bronquiectasias. Open Respiratory Archives 2020;2:215-25. [DOI: 10.1016/j.opresp.2020.05.008] [Reference Citation Analysis]
11 Puggioni F, Alves-Correia M, Mohamed MF, Stomeo N, Mager R, Marinoni M, Racca F, Paoletti G, Varricchi G, Giorgis V, Melioli G, Canonica GW, Heffler E. Immunostimulants in respiratory diseases: focus on Pidotimod. Multidiscip Respir Med 2019;14:31. [PMID: 31700623 DOI: 10.1186/s40248-019-0195-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]